Sugar Elizabeth A

Gonzales John, Acharya Nisha R, Sugar Elizabeth A, Burke Alyce E, Vitale Albert T, Gupta Vishali et al.

This study found the dexamethasone implant was most effective for uveitic macular edema over 24 weeks compared to ranibizumab or methotrexate, offering a superior treatment option despite side effects.

Jabs Douglas A, Sugar Elizabeth A, Burke Alyce E, Altaweel Michael M, Dunn James P, Gangaputra Sapna et al.

Uveitis patients on systemic therapy face high, ongoing cataract surgery risk, especially with age or topical steroids. Surgery generally yields good visual outcomes, but risk factors need careful monitoring.

Acharya Nisha R, Vitale Albert T, Sugar Elizabeth A, Holbrook Janet T, Burke Alyce E, Thorne Jennifer E et al.

The MERIT trial found dexamethasone implants are superior to methotrexate and ranibizumab for uveitic macular edema at 12 weeks, despite a higher risk of treatable IOP elevation.

Kempen John H, Van Natta Mark L, Friedman David S, Altaweel Michael M, Ansari Husam, Dunn James P et al.

This study found fluocinolone implants cause substantially higher glaucoma risk than systemic therapy in uveitis patients. Careful, indefinite IOP monitoring is crucial, as some glaucoma worsened despite expert management.